Comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma

Ended Project Grant Awarded Last action

Award ID
W81XWH2210347
Recipient
Awarding agency
Obligated
$541,681

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

About this award

Written by GovTribe AI ·

The Department of the Army Medical Command awarded a $541,681 project grant to Dana-Farber Cancer Institute, Inc. to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield injuries and other conditions. Over a four-year period ending August 2026, Dana-Farber will evaluate immune responses in neuroblastoma patients undergoing immunotherapy, chemotherapy, surgery, radiation, stem cell transplant, and other treatments to gain insights that could improve outcomes for this high-risk pediatric cancer.

Quick answers

Who received award W81XWH2210347?

W81XWH2210347 was awarded to Dana-Farber Cancer Institute, Inc. by Medical Command (Department of the Army) on September 1, 2022.

How much is award W81XWH2210347 worth?

$541,681 has been obligated on W81XWH2210347.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login